Biosense Webster Develops First AF Ablation Catheter Following Atrionix Buy
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis' $62.8 mil. cash acquisition of Atrionix rounds out Biosense Webster's electrophysiology product line with a catheter-based ablation approach to atrial fibrillation (AF).
You may also be interested in...
AF-Only Defibrillator Therapy May Be Five Years Away, Investigator Says
Implantable defibrillator therapy for the nearly 4 mil. atrial fibrillation patients not requiring ventricular defibrillation is at least three to five years away, Northwestern University electrophysiologist Alan Kadish, MD, indicated at the recent Lehman Brothers Healthcare Conference in Orlando, Florida.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”